

# RAUCON *BD Executive News*

Vol. 16 # 15 | 20 August 2020

## Hot Company News

\* Partnership: **Adalvo** has entered into a partnership with **Teva** who will be given exclusive rights for the commercialization of five biosimilar product candidates which will be developed, registered and supplied by **Alvotech**. The originator products of these five candidates currently generate around \$35 billion in U.S. sales. 5 Aug 2020 ([www.adalvo.com](http://www.adalvo.com))

\* Distribution: **Antares Pharma, Inc.** entered into an exclusive distribution agreement with **Lunatus Global Medical Supplies** to distribute and promote the sale of XYOSTED® for adult men diagnosed with testosterone deficiency in Saudi Arabia and the United Arab Emirates. 3 Aug 2020 ([www.antarespharma.com](http://www.antarespharma.com))

\* Distribution: **Bavarian Nordic A/S** initiated full commercial operations in the U.S. only eight months after completing the acquisition of the manufacturing and global rights to Rabipur®/RabAvert® (Rabies Vaccine) and Encepur® (Tick-Borne Encephalitis Vaccine) from **GlaxoSmithKline plc.** 5 Aug 2020 ([www.bavarian-nordic.com](http://www.bavarian-nordic.com))

\* Acquisition: **Bayer AG** will acquire **KaNdy Therapeutics Ltd.** to expand its drug development pipeline in women's healthcare. KaNdy Therapeutics Ltd. recently completed the Phase IIb with NT-814, a first in class, non-hormonal, once-daily, oral neurokinin-1,3 receptor antagonist. 11 Aug 2020 ([www.bayer.com](http://www.bayer.com))

\* Acquisition: **Biological E. Limited**, a Hyderabad-based pharmaceuticals & biologics company and frequently attending company of euroPLX, reported the acquisition of **Akorn India Limited**, a subsidiary of **Akorn Inc., USA**. By this strategic acquisition, BE will be able to enhance its manufacturing capabilities and capacities to produce & supply its vaccines and injectable medicines. 17 Aug 2020

([www.biologicale.com](http://www.biologicale.com))

\* Acquisition: **Cellix Bio Pharma** completed the acquisition of **Avaca Pharma**, a formulation development company. 3 Aug 2020 ([www.cellixbiopharma.com](http://www.cellixbiopharma.com))

\* Acquisition: **Arsenal Capital Partners**, a specialized private equity firm investing in healthcare and industrials companies, has completed the acquisition of **Cello Health plc**, the global healthcare-focused advisory firm, for a total enterprise value of £181.8 million. 11 Aug 2020 ([cellohealth.com](http://cellohealth.com))

\* Acquisition: **Cerevel Therapeutics, Inc.** and **Arya Sciences Acquisition Corp II** have entered into a definitive business combination agreement. Upon closing of the transaction, Arya II will redomicile as a Delaware corporation, be renamed Cerevel Therapeutics Holdings, Inc. 30 Jul 2020 ([www.cerevel.com](http://www.cerevel.com))

\* Acquisition: **Johnson & Johnson** has entered into a definitive agreement to acquire **Momenta Pharmaceuticals, Inc.**, a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately \$6.5 billion. The acquisition provides an opportunity for the **Janssen Pharmaceutical Companies** of Johnson & Johnson to broaden its leadership in immune-mediated diseases and drive further growth through expansion into autoantibody-driven disease. 19 Aug 2020 ([www.jnj.com/](http://www.jnj.com/))

\* Acquisition: **Ligand Pharmaceuticals Inc.** plans to acquire **Pfenex Inc.**, a development and licensing biotechnology company, for a total transaction value of up to \$516 million. 10 Aug 2020 ([www.ligand.com](http://www.ligand.com))

\* Acquisition: **Rafarma Pharmaceuticals** has reached an agreement to be acquired by **R. & D. Biocogency Laboratories Inc.** Ltd, a privately-owned group with an

existing portfolio of companies that manufacture and distribute generic drugs, equipment and drugs for nuclear medicine. 4 Aug 2020 ([rafarma.si/](http://rafarma.si/))

\* Distribution: **Regeneron Pharmaceuticals, Inc.** and **Roche** are joining forces in the fight against COVID-19 to develop, manufacture and distribute REGN-COV2, Regeneron's investigational antiviral antibody cocktail, to people around the globe. Regeneron will distribute REGN-COV2 in the U.S. and Roche will be responsible for distribution outside the U.S. 19 Aug 2020 ([www.regeneron.com](http://www.regeneron.com))

\* Acquisition: **Sanofi** and **Principia Biopharma Inc.**, a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Principia for \$100 per share in cash, which represents an aggregate equity value of approximately \$3.68 billion (on a fully diluted basis). 17 Aug 2020 ([www.sanofi.com](http://www.sanofi.com))

\* Acquisition: **SIT Laboratorio Farmaceutico** acquired LOPRESSOR®, ICAZ® and MIOREL® from **Daiichi Sankyo France**. 3 Aug 2020 ([www.sit-farmaceutici.com](http://www.sit-farmaceutici.com))

\* Licensing: **Lexicon Pharmaceuticals, Inc.** and **TerSera Therapeutics LLC** have entered into an asset purchase and sale agreement for the sale to TerSera of Lexicon's rights, title and interest in XERMELO® (telotristat ethyl) which plays role in carcinoid syndrome diarrhea. 30 Jul 2020 ([www.tersera.com](http://www.tersera.com))

\* Licensing: **TFF Pharmaceuticals, Inc.**, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, entered into a worldwide exclusive

licensing agreement with **UNION therapeutics A/S** for its TFF technology used in combination with niclosamide. 13 Aug 2020 ([tffpharma.com](http://tffpharma.com))

\* Acquisition: **Viva Biotech (Shanghai) Ltd.** agreed to acquire 80% of the equity interest in **Langhua Pharmaceutical** for RMB2,560 million (equivalent to approximately HK\$2,842 million) in cash. 8 Aug 2020 ([www.vivabio-tech.com](http://www.vivabio-tech.com))

## BD People on the Move

\* Alfred E. Tiefenbacher: **Dennis Kuck**, until most recently with Chemo Group as Senior Commercial Manager has been appointed as Director Key Account & Licensing. (Pers Comm 3 Aug 2020)

\* Intas Pharmaceuticals Ltd.: **Paulo Rodriguez**, who has been Business Development and Licensing Manager left the company effective 6 August 2020 in order to pursue other opportunities. (Pers Comm 11 Aug 2020)

\* medac GmbH: **Patrick Tichy**, previously with Centrient as Licensing and Sales Manager, and a frequent euroPLX attendee and Bell Club Member, has been appointed as Business Development & Licensing Manager Global Business Innovative Therapeutics. (Pers Comm 19 Aug 2020)

\* Werewolf Therapeutics, Inc.: **Ellen Lubman**, who joins from Impel NeuroPharma, where she was Chief Business Officer, has been appointed to the company's newly created position of Chief Business Officer and will oversee corporate and business development. (Press Release 10 Aug 2020)

\* XORTX Therapeutics Inc.: Dr. **David Sans** has been appointed as Director, Corporate Development to be based in New York City. (Press Release 7 Aug 2020)